

Ref: Outcome/BM/02.08.2025

August 2, 2025

The General Manager
Department of Corporate Services
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400001.
Scrip Code: 524075

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C-1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051.
Symbol: ALBERTDAVD

Dear Sir / Madam,

Sub: Outcome of the Board Meeting

In terms of Regulation 30, 33 and Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”) read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, we inform/submit as follows.

The Board of Directors in their meeting held today, i.e., 2nd August, 2025 have, *inter-alia*, transacted / taken decision on the following items of business:

1. Considered, approved and taken on record the Unaudited Financial Results for the first Quarter ended 30th June, 2025 and the Limited Review Report of the Auditors thereon and approve publication of the Results in the newspaper. The said financials is annexed herewith as **Annexure - A**.
2. Based on the recommendation of the Nomination and Remuneration Committee, the Board has considered and approved appointment of Dr. Rajiv Anant Desai (DIN: 11193975) as an Additional -Non Executive Independent Director of the Company w.e.f 2nd August, 2025 to hold office for a period of 5 (Five) consecutive years, subject to approval of the shareholders of the Company by means of Postal Ballot. The aforesaid Director is not debarred from holding office of Directors pursuant to any order of Securities Exchange Board of India. Pursuant to SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09/09/2015, the brief profile is annexed herewith as **Annexure B**.
3. Approved the Postal Ballot Notice for obtaining shareholders’ approval for appointment of Dr. Rajiv Anant Desai (DIN: 11193975) as Non-Executive Independent Director of the Company.

The Board Meeting commenced at 12:00 P.M. and concluded at 16:40 P.M.

We request you to take the above on record.

Thanking you,
Yours faithfully,
For **Albert David Limited**

(Lalit Lohia)
Company Secretary & Compliance Officer

Encl.: As above

Limited Review Report

To
 The Board of Directors
 Albert David Limited

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of **Albert David Limited** ("the Company"), for the quarter ended June 30, 2025.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Kolkata
 Date: 02.08.2025



For L.B. Jha & Co.,
 Chartered Accountants
 (Registration Number: 301088E)

(Signature)
 (D.N. Roy)
 Partner

(Membership No. 300389)
 UDIN: 25300389BMHWRP5828

**ALBERT DAVID LIMITED****Regd. Office : 'D' Block, 3rd Floor, Gillander House, Netaji Subhas Road, Kolkata-700001****(Corporate Identity No. : L51109WB1938PLC009490)****Tel : 033-2262-8436/8456/8492, 2230-2330****Email : albertdavid@adlindia.in, Website : www.albertdavidindia.com****STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025**

Sl. No.	Particulars	Quarter Ended			Year ended
		30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Audited)	31.03.2025 (Audited)
1	Income				
	(a) Revenue from operations	7,056.64	7,489.33	8,935.64	34,576.80
	(b) Other Income	2,203.62	-511.44	2,306.23	2,958.07
	Total Income	9,260.26	6,977.89	11,241.87	37,534.87
2	Expenses				
	a) Cost of materials consumed	1,324.80	2,089.51	1,549.57	7,015.05
	b) Purchases of stock-in-trade	991.22	1,855.06	1,292.40	6,046.24
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	211.98	-1,012.04	188.05	-1,432.98
	d) Employee Benefits expenses	2,843.02	2,268.18	2,836.57	10,902.46
	e) Finance Costs	55.48	13.15	9.32	41.04
	f) Depreciation and Amortization expenses	238.87	181.75	178.50	696.89
	g) Other expenses	2,751.06	2,763.15	2,981.24	11,743.40
	Total Expenses	8,416.43	8,158.76	9,035.65	35,012.10
3	Profit/(Loss) before Exceptional Items and Tax (1-2)	843.83	-1,180.87	2,206.22	2,522.77
4	Exceptional Items	-	-	-	-
5	Profit/(Loss) before tax (3-4)	843.83	-1,180.87	2,206.22	2,522.77
6	Tax Expenses				
	(a) Current Tax	-	178.84	118.17	592.42
	(b) Deferred Tax	50.07	-326.92	203.61	210.27
7	Profit/(Loss) for the Period (5-6)	793.76	-1,032.79	1,884.44	1,720.08
8	Other Comprehensive Income				
	(a) (i) Items that will not be reclassified to profit or loss	-24.54	-161.53	27.14	-38.60
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.18	43.76	-6.83	-74.90
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
9	Total Comprehensive Income for the period (7 + 8)	775.40	-1,150.56	1,904.75	1,606.58
10	Paid-Up Equity Share Capital (Face value of Rs.10/-)	570.72	570.72	570.72	570.72
11	Other Equity	-	-	-	38,677.62
12	Earning Per Equity Share of Rs.10/- each (not annualised)				
	(a) Basic (Rs.)	13.91	-18.10	33.02	30.14
	(b) Diluted (Rs.)	13.91	-18.10	33.02	30.14

Notes :

- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 2nd August, 2025. The Limited Review for the quarter ended 30th June, 2025 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LO&DR) Regulations, 2015.
- The Statutory Auditors of the Company have issued an unmodified review report on the Unaudited Financial Results for the quarter ended 30th June, 2025
- The Company is engaged in the manufacturing of pharmaceuticals and has only one reportable segment in accordance with Ind AS-108 "Operating Segments".
- Figures for the quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the figures upto the end of third quarter
- Figures for the previous periods are regrouped to conform to the figures of the current period as and when required in limited context of format of financial results and disclosures thereon specified by SEBI.



Place : Kolkata
Date : 2nd August, 2025

For ALBERT DAVID LIMITED

(U. M. Kunte)
Managing Director & CEO
(DIN : 03398438)



Annexure B

Disclosure of information pursuant to Regulation 30 (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Name	Dr. Rajiv Anant Desai
Reason for Change viz. appointment.	Appointed Dr. Rajiv Anant Desai (DIN: 11193975) as an Additional Director (designated as Non-Executive Independent Director) of the Company for a period of 5 (five) years with effect from 2 nd August, 2025, subject to the approval of shareholders of the Company in the General Meeting (By means of ensuing Postal Ballot).
Date of appointment	2 nd August, 2025 for a period of 5 (five) years.
Terms of Appointment	As placed on the Company's website https://www.albertdavidindia.com
Brief Profile	Dr. Rajiv Anant Desai, aged 63 years is a M.Sc (Chemistry) Graduate from Mumbai University, an Ph.D in Pharmaceutical Chemistry from ICT Mumbai Institute of Chemical Technology (ICT) and MBA from NMIMS, Mumbai. He carries more than 38 years' experience in several geographies around the world. Since July 2022, He is working as Senior Technical Advisor-Quality and Regulatory with Indian Pharmaceutical Alliance (IPA). Also, he is Independently working as a freelancing consultant and Advisor for the Pharma Industry. He held the position of Executive Vice President, Global Corporate Quality between June 2016 to June 2022 at Lupin Limited. He started career with Ciba Geigy (now Novartis) in R&D and Technology transfers with assignments in India and Switzerland. He was member of US Pharmacopeia Expert Committee (2010 – 2015) and currently supporting USP workshops and seminars as an invited speaker for topics in Pharma Industry. He holds membership in Indian Pharmacopoeia Expert committee. He was nominated by the Ministry of Chemicals and Fertilizers, Dept. of Pharmaceuticals, Govt of India as member of Board of Governors for the National Institute of Pharmaceutical Education and Research (NIPER). He received the Chairman's Excellence Award for best Quality Management and best Customer Retention Initiative at Dr Reddy's

	Laboratories. He is a visiting faculty at NMIMS, BITS, Pillani, MS University for Post graduate courses. He is also on the Board of Studies at three Chemistry and one Pharmacy colleges in Mumbai, INDIA for Syllabus Setting and Ph.D Research.
Disclosure of relationships between Directors	Dr. Rajiv Anant Desai is not related to any of the Directors or Promoters of the Company.
Information as required under Circular No.: LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively.	Dr. Rajiv Anant Desai is not debarred from holding office of an Independent Director.